statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Biomea Fusion (BMEA Research Report), retaining the price target of $90.00. Yigal No...

Promising Efficacy of Biomea Fusion's BMF-219 in Type 1 Diabetes Treatment: A Positive Outlook on Early Clinical Data

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM Research Report), Baxter International...

Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)

Investors eyeing a purchase of Biomea Fusion Inc (BMEA) shares, but cautious about paying the going market price of 13.61/share, might benefit from considering selling puts among the alternative...

Commit To Buy Biomea Fusion At $7.50, Earn 21.8% Annualized Using Options

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ( Biomea or the Company ), a clinical stage biopharmaceutical company focused on the discovery and...

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023.
The post BMEA...

BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023

Biomea Fusion GAAP EPS of -$0.98

In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy...

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

In trading on Thursday, shares of Biomea Fusion Inc (BMEA) crossed above their 200 day moving average of 17.24, changing hands as high as 17.25 per share. Biomea Fusion Inc shares are...

Biomea Fusion Breaks Above 200-Day Moving Average - Bullish for BMEA

For the last three days, A.I.dvisor has detected that BMEA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Biomea Fusion (BMEA, $15.62) Aroon Indicator entered a Downtrend on March 12, 2024.

Biomea Fusion (BMEA, $15.41) Aroon Indicator entered a Downtrend on March 11, 2024.

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Volume	583,288.00
52-Wk High	$43.69
52-Wk Low	$8.13

BMEA Biomea Fusion Inc

About

Feed

News

Sentiment

Earnings

Fundamentals